MOB — Moberg Pharma AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK434.29m
- SEK213.93m
- SEK13.54m
Brief: Moberg Pharma Announces The Final Terms Of The Rights Issue
Brief: Moberg Pharma: Approval For MOB-015 In Sweden
Brief: Moberg Pharma Expects National Approvals For New Onychomycosis Treatment
Brief: Moberg Pharma's MOB-015 Gets Market Authorisation In Ireland
Brief: Moberg Pharma Resolves On Rights Issue Of About SEK 100 Mln
Brief: Moberg Pharma BOD Resolves Record Date For Reverse Share Split
Brief: Moberg Pharma Q1 Operating Loss Widens To SEK 6.7 Mln
Brief: Moberg Pharma Regains Full Rights To Mob-015 In Japan
Brief: Moberg Pharma Q4 EBIT Loss of SEK 4.6 Million
Brief: Moberg Pharma Q3 EBITDA Loss Widens To SEK 4.6 Million
Brief: Moberg Pharma Q2 Loss Widens To SEK 3.9 Mln
Brief: Moberg Pharma And Padagis Sign Agreement For MOB-015 In Israel
Brief: Moberg Pharma Resolves On Directed Issue Of Ordinary Shares To Guarantors In Connection With Completed Rights Issue
Brief: Moberg Pharma Announces Outcome Of Rights Issue Of Ordinary Shares
Brief: Moberg Pharma Q1 EBITDA Loss Narrows To SEK 4.8 Million
Brief: Moberg Pharma Decides On A Fully Guaranteed Rights Issue Of About SEK 121 Million
Brief: Moberg Pharma Announces Outcome Of Exercise Of Warrants Of Series 20201
Brief: Moberg Pharma Q4 EBIT Loss Narrows To SEK 4.9 Million
Brief: Moberg Pharma Proposes Kerstin Valinder Strinnholm As New Chairman